Oxford Biomedica PLC. Stock Analysis OXB.L

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire and currently employs 900 full-time employees. The firm is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. The company offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.